X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Allogeneic TCR-T cell therapies
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Poseida Therapeutics, Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 21, 2020
Details:
Collaboration leverages TScan's proprietary high-throughput TCR/Target discovery platform and poseida's proprietary allogeneic T cell approach to advance potential TCR-T treatments.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SARS-CoV-2 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Vaccine
Partner/Sponsor/Collaborator: CVC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 13, 2020
Details:
Ardigen's neoantigen prediction platform called "ArdImmune Vax" employs state of the art bioinformatics and Artificial Intelligence to identify an optimal set of neoantigens as targets for cancer vaccines or adoptive cell therapies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Vaccine
Partner/Sponsor/Collaborator: Merck & Co. Inc.
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Agreement May 28, 2020
Details:
Under the collaboration agreement, originally signed in 2012, through the exercise of this option MSD gains exclusive worldwide rights to develop and commercialize an undisclosed vaccine utilizing Vaxxas’ HD-MAP technology.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
